2015
DOI: 10.1158/1535-7163.targ-15-c194
|View full text |Cite
|
Sign up to set email alerts
|

Abstract C194: Repression of tumor survival pathways by novel and selective inhibitors of MNK1 and MNK2 kinases in cancer

Abstract: Herewith, we report development of small molecule inhibitors of MNK1 and MNK2 kinases and their cellular activity. MNK1 and 2 are MAP kinase-interacting kinases are activated by RAS and MAPK signaling pathways, and are involved in regulation of translation. Both kinases phosphorylate translation initiation factor eIF4e on a conserved serine 209. eIF4E can contribute to the oncogenic transformation both in vitro and in vivo and is highly expressed in diverse types of cancer. Interestingly, mice that lack both M… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Pyridone-based compounds were reported as potent MNK1 and MNK2 inhibitors. The majority of the compounds in this patent exhibited an indazolyl-pyridyl core.…”
Section: Inhibitors Of Mnk1/2mentioning
confidence: 99%
“…Pyridone-based compounds were reported as potent MNK1 and MNK2 inhibitors. The majority of the compounds in this patent exhibited an indazolyl-pyridyl core.…”
Section: Inhibitors Of Mnk1/2mentioning
confidence: 99%